Cisplatin resistance and opportunities for precision medicine

Pharmacological Research

Volumn 106, Issue , 2016, Pages 27-36

  Amable, Lauren ^a  

^a NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES   (United States)

Author keywords

ABC transporters; Cisplatin resistance; Copper transporters; ERCC1; Glutathione; Nucleotide excision repair

Indexed keywords

BIOLOGICAL MARKER; CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER PROTEIN 1; COPPER TRANSPORTER PROTEIN 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE M2; GLUTATHIONE TRANSFERASE M3; GLUTATHIONE TRANSFERASE M4; GLUTATHIONE TRANSFERASE M5; GLUTATHIONE TRANSFERASE P1; MENKES PROTEIN; METALLOTHIONEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN; ANTINEOPLASTIC AGENT;

3' UNTRANSLATED REGION; CANCER RESISTANCE; CANCER SURVIVAL; DNA DAMAGE; DNA REPAIR; DRUG BINDING; DRUG INACTIVATION; DRUG SENSITIVITY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; SURVIVAL TIME; UPREGULATION; DRUG EFFECTS; DRUG RESISTANCE; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84959156515     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.001     Document Type: Review

References (152)

1. B. Rosenberg, L. Vancamp, and T. Krigas Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698 699
2. B. Rosenberg, and et al. Platinum compounds: a new class of potent antitumour agents Nature 222 5191 1969 385 386
3. E. Reed Cisplatin, carboplatin, and oxaliplatin B.A. Chabner, D.L. Longo, Cancer Chemotherapy and Biotherapy: Principles and Practice 4th edition 2006 Lippincott, Williams, & Wilkins Philadelphia 332 343
4. E. Reed, and B.A. Chabner Platinum analogues B.A. Chabner, D.L. Longo, Cancer Chemotherapy and Biotherapy: Principles and Practice 5th edition 2011 Lippincott, Williams and Wilkins Philadelphia 310 322
5. P. Perego, and J. Robert Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy Cancer Chemother. Pharmacol. 77 2016 5 18
6. M. Markman, and et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J. Clin. Oncol. 9 3 1991 389 393
7. A. Eastman, and N. Schulte Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II) Biochemistry 27 13 1988 4730 4734
8. V.M. Richon, N. Schulte, and A. Eastman Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells Cancer Res. 47 8 1987 2056 2061
9. K.V. Ferry, T.C. Hamilton, and S.W. Johnson Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF Biochem. Pharmacol. 60 9 2000 1305 1313
10. S.W. Johnson, and et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines Biochem. Pharmacol. 47 4 1994 689 697
11. R. Metzger, and et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy J. Clin. Oncol. 16 1 1998 309 316
12. Q. Li, and et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells Anticancer Res. 20 2A 2000 645 652
13. M. Dabholkar, and et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J. Natl. Cancer Inst. 84 19 1992 1512 1517
14. E. Reed, and et al. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer Clin. Cancer Res. 9 14 2003 5299 5305
15. M. Ulker, and et al. ERCC1 and RRM1 as a predictive parameter for non-small cell lung: ovarian or pancreas cancer treated with cisplatin and/or gemcitabine Contemp. Oncol. (Pozn.) 19 3 2015 207 213
16. J.A. Deloia, and et al. Comparison of ERCC1/XPF genetic variation: mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum Gynecol. Oncol. 126 3 2012 448 454
17. E. Cubukcu, and et al. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome Clin. Transl. Oncol. 13 11 2011 826 830
18. K.J. Xie, and et al. Expression of ERCC1: MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy Asian Pac. J. Cancer Prev. 15 6 2014 2591 2596
19. Z. Li, and et al. Predictive value of APE1: BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy Cancer Chemother. Pharmacol. 74 4 2014 777 786
20. F. Yamashita, and et al. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy PLoS One 8 8 2013 e71356
21. C. Li, and et al. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer Tumour Biol. 35 12 2014 12707 12712
22. M. Tiseo, and et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin Br. J. Cancer 108 8 2013 1695 1703
23. R.V. Lord, and et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin. Cancer Res. 8 7 2002 2286 2291
24. P.Y. Huang, and et al. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy Oral Oncol. 48 10 2012 964 968
25. Z. Zhang, C. Jiang, and L. Hu Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy Tumori 100 3 2014 328 332
26. J. Huang, and et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy Med. Oncol. 30 1 2013 343
27. Z.L. Bai, and et al. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma Radiat. Oncol. 7 2012 221
28. A.O. Zwenger, and et al. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens Int. J. Biol. Markers 30 3 2015 e301 14
29. M. Xuelei, and et al. ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: a meta-analysis Oral Oncol. 51 5 2015 483 492
30. M. Ciaparrone, and et al. Predictive role of ERCC1 expression in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation Oncology 89 4 2015 227 234
31. S. Ueda, and et al. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma Ann. Surg. Oncol. 18 4 2011 1204 1211
32. C.M. Hattinger, and et al. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade: non-metastatic osteosarcoma treated with neoadjuvant chemotherapy Histopathology 67 3 2015 338 347
33. T.C. Lai, and et al. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients Oncol. Rep. 25 5 2011 1243 1251
34. I.G. Hwang, and et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients Cancer Chemother. Pharmacol. 68 4 2011 935 944
35. S. Ting, and et al. ERCC1, MLH1, MSH2 MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma Clin. Lung Cancer 14 5 2013 558 567 e3
36. S.H. Lee, and et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin Lung Cancer 81 1 2013 102 108
37. J.J. Yu, and et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues Mutat. Res. 382 1-2 1997 13 20
38. J.J. Yu, and et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum: but differ at codon 118 of the ERCC1 gene Int. J. Oncol. 16 3 2000 555 560
39. E. Reed ERCC1 and clinical resistance to platinum-based therapy Clin. Cancer Res. 11 17 2005 6100 6102
40. S. Smith, and et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J. Clin. Oncol. 25 33 2007 5172 5179
41. R. Gao, and et al. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity Mutat. Res. 708 1-2 2011 21 27
42. J. Viguier, and et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin. Cancer Res. 11 17 2005 6212 6217
43. H. Kamikozuru, and et al. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy Int. J. Oncol. 32 5 2008 1091 1096
44. T. Hao, and et al. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients Asian Pac. J. Cancer Prev. 13 8 2012 3821 3824
45. Z.H. Shi, G.Y. Shi, and L.G. Liu Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer Int. J. Clin. Exp. Pathol. 8 3 2015 3132 3137
46. J. Cheng, and et al. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer J. Cancer Res. Clin. Oncol. 138 2 2012 231 238
47. J.S. Ryu, and et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy Lung Cancer 44 3 2004 311 316
48. P. Chen, and et al. Association of an ERCC1 polymorphism with adult-onset glioma Cancer Epidemiol. Biomarkers Prev. 9 8 2000 843 847
49. W. Zhou, and et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy Clin. Cancer Res. 10 15 2004 4939 4943
50. Y. Wang, and et al. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma Oncol. Rep. 25 4 2011 1047 1052
51. C. Chen, and et al. Polymorphisms in ERCC1C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy Cancer Chemother. Pharmacol. 72 2 2013 315 322
52. T.P. Xu, and et al. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports Gene 526 2 2013 265 274
53. M. Dabholkar, and et al. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues Biochem. Pharmacol. 60 11 2000 1611 1619
54. J. Yu, and et al. Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53: ERCC1 and XPA Int. J. Oncol. 8 2 1996 313 317
55. E.V. Stevens, and et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers Mol. Cancer Ther. 7 1 2008 10 18
56. B. Koberle, and et al. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo Int. J. Oncol. 36 5 2010 1277 1284
57. A. Vaezi, and et al. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck Clin. Cancer Res. 17 16 2011 5513 5522
58. D.A.et al. Weaver ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines Mol. Cancer 4 1 2005 18
59. R. Aloyz, and et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD Cancer Res. 62 19 2002 5457 5462
60. M.R. Spitz, and et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients Cancer Res. 61 4 2001 1354 1357
61. K. Goricar, and et al. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma Cancer Epidemiol. 39 2 2015 182 188
62. G.J. Peters, and et al. Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancer Anticancer Res. 34 1 2014 435 442
63. V. Ludovini, and et al. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response: toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients J. Thorac. Oncol. 6 12 2011 2018 2026
64. D.P. Gately, and S.B. Howell Cellular accumulation of the anticancer agent cisplatin: a review Br. J. Cancer 67 6 1993 1171 1176
65. E.S. Kim, and et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer J. Clin. Oncol. 30 27 2012 3345 3352
66. H. Eichholtz-Wirth, and B. Hietel The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro Br. J. Cancer 54 2 1986 239 243
67. G.R. Gale, and et al. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents Cancer Res. 33 4 1973 813 818
68. M.D. Hall, and et al. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy Annu. Rev. Pharmacol. Toxicol. 48 2008 495 535
69. X. Lin, and et al. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae Mol. Pharmacol. 62 5 2002 1154 1159
70. K. Katano, and et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper Cancer Res. 62 22 2002 6559 6565
71. J. Zisowsky, and et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells Biochem. Pharmacol. 73 2 2007 298 307
72. Z.D. Liang, and et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents Mol. Cancer Ther. 11 11 2012 2483 2494
73. S. Ishida, and et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator Cancer Cell 17 6 2010 574 583
74. H.H. Chen, and et al. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy Lung Cancer 75 2 2012 228 234
75. E.S. Kim, and et al. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer Lung Cancer 85 1 2014 88 93
76. X. Xu, and et al. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients Clin. Exp. Pharmacol. Physiol. 39 9 2012 786 792
77. N.K. Wee, and et al. The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease Int. J. Biochem. Cell Biol. 45 5 2013 960 963
78. P.V. van den Berghe, and et al. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake Biochem. J. 407 1 2007 49 59
79. B.G. Blair, and et al. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin Clin. Cancer Res. 15 13 2009 4312 4321
80. Y.Y. Lee, and et al. Prognostic value of the copper transporters: CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy Gynecol. Oncol. 122 2 2011 361 365
81. H. Yoshida, and et al. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer Anticancer Res. 33 4 2013 1409 1414
82. K.K. Filipski, and et al. Interaction of cisplatin with the human organic cation transporter 2 Clin. Cancer Res. 14 12 2008 3875 3880
83. H. Burger, and et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) Br. J. Pharmacol. 159 4 2010 898 908
84. A. Naka, and et al. Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer Am. J. Cancer Res. 5 7 2015 2285 2293
85. Y. Wang, and et al. The association of transporter genes polymorphisms and lung cancer chemotherapy response PLoS One 9 3 2014 e91967
86. E. Luk, L.T. Jensen, and V.C. Culotta The many highways for intracellular trafficking of metals J. Biol. Inorg. Chem. 8 8 2003 803 809
87. Z.H. Li, and et al. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC) J. Transl. Med. 10 2012 21
88. G. Samimi, and et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin: carboplatin, and oxaliplatin in ovarian cancer cells Clin. Cancer Res. 10 14 2004 4661 4669
89. G. Samimi, and et al. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients Clin. Cancer Res. 9 16 Pt 1 2003 5853 5859
90. Y. Inoue, and et al. Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer Oncol. Lett. 1 5 2010 837 840
91. J.H. Deng, and et al. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients Clin. Transl. Oncol. 17 9 2015 720 726
92. M. Komatsu, and et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance Cancer Res. 60 5 2000 1312 1316
93. H. Sugeno, and et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) in human hepatocellular carcinoma Anticancer Res. 24 2C 2004 1045 1048
94. M. Ohbu, and et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma Cancer Lett. 189 1 2003 33 38
95. M. Higashimoto, and et al. Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma Int. J. Mol. Med. 11 3 2003 337 341
96. H. Miyashita, and et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin Oral Oncol. 39 2 2003 157 162
97. A. Kanzaki, and et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma Jpn. J. Cancer Res. 93 1 2002 70 77
98. T. Aida, and et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma Gynecol. Oncol. 97 1 2005 41 45
99. K. Nakayama, and et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy Clin. Cancer Res. 10 8 2004 2804 2811
100. K. Nakayama, and et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP Int. J. Cancer 101 5 2002 488 495
101. Y. Inoue, and et al. ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer Oncol. Lett. 1 2 2010 279 282
102. H. Burger, and et al. Drug transporters of platinum-based anticancer agents and their clinical significance Drug Resist. Updat. 14 1 2011 22 34
103. T. Ishikawa, C.D. Wright, and H. Ishizuka GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation J. Biol. Chem. 269 46 1994 29085 29093
104. S.P. Cole, and et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res. 54 22 1994 5902 5910
105. K. Ikuta, and et al. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells Biol. Pharm. Bull. 28 4 2005 707 712
106. P. de Cremoux, and et al. Role of chemotherapy resistance genes in outcome of neuroblastoma Pediatr. Blood Cancer 48 3 2007 311 317
107. K. Taniguchi, and et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation Cancer Res. 56 18 1996 4124 4129
108. M. Kool, and et al. Analysis of expression of cMOAT (MRP2): MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res. 57 16 1997 3537 3547
109. P. Borst, M. Kool, and R. Evers Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin. Cancer Biol. 8 3 1997 205 213
110. W.K. Kaufmann, and et al. TGF-alpha sustains clonal expansion by promoter-dependent: chemically initiated rat hepatocytes Carcinogenesis 18 7 1997 1381 1387
111. E. Hinoshita, and et al. Increased expression of an ATP-binding cassette superfamily transporter: multidrug resistance protein 2, in human colorectal carcinomas Clin. Cancer Res. 6 6 2000 2401 2407
112. M. Yamasaki, and et al. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma Br. J. Cancer 104 4 2011 707 713
113. P.V. Korita, and et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma Oncol. Rep. 23 4 2010 965 972
114. Y. Ohishi, and et al. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma Clin. Cancer Res. 8 12 2002 3767 3775
115. M. Filipits, and et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program Clin. Cancer Res. 13 13 2007 3892 3898
116. N. Sun, and et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer Cancer Chemother. Pharmacol. 65 3 2010 437 446
117. B. Han, and et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients Lung Cancer 72 2 2011 238 243
118. C.A. Rabik, and M.E. Dolan Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat. Rev. 33 1 2007 9 23
119. S.S. Byun, and et al. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities BJU Int. 95 7 2005 1086 1090
120. A.K. Godwin, and et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc. Natl. Acad. Sci. U. S. A. 89 7 1992 3070 3074
121. S. Goto, and et al. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs Jpn. J. Cancer Res. 93 9 2002 1047 1056
122. T. Satoh, and et al. Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors Eur. J. Obstet. Gynecol. Reprod. Biol. 96 2 2001 202 208
123. P. Surowiak, and et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients Virchows Arch. 447 3 2005 626 633
124. T. Nishimura, and et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer Clin. Cancer Res. 2 11 1996 1859 1865
125. K. Nakagawa, and et al. Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin Jpn. J. Cancer Res. 79 3 1988 301 304
126. K.H. Kim, and et al. Clinicopathologic significance of ERCC1: thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy Biomarkers 16 1 2011 74 82
127. T. Arai, and et al. Correlation between the immunohistochemical and mRNA expression of glutathione S-transferase-pi and cisplatin plus etoposide chemotherapy response in patients with untreated primary non-small cell lung cancer Int. J. Oncol. 11 1 1997 127 131
128. T. Arai, and et al. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer Cancer Detect. Prev. 24 3 2000 252 257
129. T. Hirano, and et al. Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker Int. J. Cancer 117 3 2005 460 468
130. K. Ikeda, and et al. Multivariate analysis for prognostic significance of histologic subtype: GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer Int. J. Gynecol. Cancer 13 6 2003 776 784
131. A.G. van der Zee, and et al. Value of P-glycoprotein: glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas J. Clin. Oncol. 13 1 1995 70 78
132. I. Konishi, and et al. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma Gynecol. Oncol. 70 3 1998 365 371
133. M.A. Watson, and et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis 19 2 1998 275 280
134. H. Lv, and et al. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer Med. Oncol. 31 8 2014 86
135. X. Wu, and et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy Pharmacogenet. Genomics 18 11 2008 955 965
136. C. Lu, and et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma Cancer 106 2 2006 441 447
137. Y. Saburi, and et al. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line Cancer Res. 49 24 Pt 1 1989 7020 7025
138. A.J. Townsend, C.P. Tu, and K.H. Cowan Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents Mol. Pharmacol. 41 2 1992 230 236
139. D.J. Waxman, and et al. Gene-specific oligonucleotide probes for alpha, mu, pi, and microsomal rat glutathione S-transferases: analysis of liver transferase expression and its modulation by hepatic enzyme inducers and platinum anticancer drugs Cancer Res. 52 20 1992 5797 5802
140. M.B. Watson, and et al. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model Acta Oncol. 46 5 2007 651 658
141. L. Smith, and et al. The proteomic analysis of cisplatin resistance in breast cancer cells Oncol. Res. 16 11 2007 497 506
142. C.H. Wang, and et al. Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells J. Med. Chem. 54 24 2011 8574 8581
143. H.E. Wheeler, and et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations Pharmacogenomics J. 13 1 2013 35 43
144. Y. Yang, and L. Xian The association between the GSTP1 A313 G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis Tumour Biol. 35 7 2014 6791 6799
145. Y.Y. Yang, and et al. Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells Mol. Pharmacol. 45 3 1994 453 460
146. K. Kasahara, and et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin Cancer Res. 51 12 1991 3237 3242
147. M.J. Siegsmund, and et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins Urol. Res. 27 3 1999 157 163
148. S.L. Kelley, and et al. Overexpression of metallothionein confers resistance to anticancer drugs Science 241 4874 1988 1813 1815
149. S.E. Theocharis, A.P. Margeli, and A. Koutselinis Metallothionein: a multifunctional protein from toxicity to cancer Int. J. Biol. Markers 18 3 2003 162 169
150. C. Meijer, and et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours Int. J. Cancer 85 6 2000 777 781
151. Y. Hishikawa, and et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer Oncology 54 4 1997 342 347
152. J.G. Schneider, and et al. Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer Oncologist 19 5 2014 459 465